

# PROVIDER Update



CONTRACTUAL | JANUARY 4, 2024 | UPDATE 24-019m | 4 PAGES

## Medication Trend Updates and Formulary Changes – 1st Quarter 2024

### Review formulary changes and medication safety issues

Stay up to date with information about:

- FDA updated boxed warnings to improve safe use of prescription stimulants to treat attention-deficit/hyperactivity disorder (ADHD).
- Changes to the Health Net\* commercial Formulary, Medi-Cal Preferred Drug List (PDL) and Medicare Part D Formulary for the first quarter of 2024.

#### FDA updated boxed warnings to improve safe use of prescription stimulants to treat ADHD

In an effort to address the harms of misuse and abuse of stimulants prescribed to treat conditions such as ADHD, the U.S. Food and Drug Administration updated warnings on the labels of prescription stimulants.

The updated boxed warnings in the prescribing information for the entire class of prescription stimulants will include information about the risks of abuse, misuse, addiction, and overdose, as well as language advising physicians to monitor patients closely for these risks. Commonly prescribed drugs in this class include amphetamine/dextroamphetamine (Adderall), methylphenidate (Concerta), dextroamphetamine (Dexedrine), lisdexamfetamine dimesylate (Vyvanse), and methylphenidate (Ritalin). These medications are indicated for the management of ADHD as well as eating disorders and narcolepsy.

This labeling update was based on a review of medical literature (between January 2006 and May 2020) on nonmedical use of prescription stimulants. Family members and friends were the most common source of prescription stimulants for nonmedical use. According to the literature, use of prescription stimulants by individuals who were not prescribed these medications has been associated with a higher risk of developing substance use disorder and addiction.

The new labeling advises health care professionals to monitor patients for obvious signs of abuse or addiction. Patients should be counseled not to share their prescribed stimulants with anyone else. Health care providers are encouraged to educate both patients and families about the serious risks of these drugs as well as proper storage and disposal of any unused medicine. In addition, careful records

#### THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups

#### LINES OF BUSINESS:

- IFP
  - Ambetter HMO
  - Ambetter PPO
- Employer Group
  - HMO/POS/HSP
  - EPO
  - PPO
- Medicare Advantage (HMO/PPO) (Wellcare By Health Net)
- Medi-Cal
  - Amador
  - Calaveras
  - Inyo
  - Los Angeles
  - Sacramento
  - San Joaquin
  - Stanislaus
  - Tulare
  - Tuolumne
- Mono

#### PROVIDER SERVICES

provider\_services@healthnet.com

**Ambetter from Health Net IFP**

**Ambetter PPO** – 844-463-8188

**Ambetter HMO** – 888-926-2164

**Health Net Employer Group HMO, POS, PPO**  
– 800-641-7761

**Medicare (individual & employer group) (Wellcare By Health Net)** – 800-929-9224

**Medi-Cal (including CS and ECM providers)** – 800-675-6110

#### PROVIDER PORTAL

provider.healthnetcalifornia.com

#### PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

\* Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

---

should be kept that indicate the quantity, frequency, and renewal requests for these medications.

## **Changes to the Commercial Formulary, Medi-Cal PDL and Medicare Part D Formulary/ Drug benefit changes**

The Health Net Pharmacy and Therapeutics (P&T) Committee includes practicing physicians, pharmacists and other health care professionals. Each quarter, the P&T Committee reviews medications on the Formulary for

commercial members, the PDL for Medi-Cal members, and the Medicare Part D Formulary for Medicare members to determine which medications remain on the same tier and which are moved. A table listing some recent changes is available on page 3-4. The list contains brand-name prescription medications, status, other medication choices, and comments for the first quarter of 2024.

The complete lists of the commercial Formularies, Medi-Cal PDLs and Medicare Part D Formularies are available on the Health Net provider website.

### **Pharmacy help line**

For more information regarding changes to the Health Net Commercial Formulary or Health Net Medi-Cal Preferred Drug List, or Medicare Part D Formulary, contact the proper pharmacy phone numbers listed below:

<b>Product</b>	<b>Phone number</b>	<b>Fax number</b>
Pharmacy Benefit (Medi-Cal Rx)	800-977-2273	800-869-4325
Medical Benefit Drugs (Medi-Cal)	800-675-6110	833-953-3436
Commercial Pharmacy Services	800-548-5524, option #3	866-399-0929
Medicare Pharmacy Service Center	800-867-6564	800-977-8226

### **Additional information**

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center at:

<b>Line of Business</b>	<b>Phone number</b>	<b>Email address</b>
<b>IFP Ambetter PPO</b>	844-463-8188	provider_services@healthnet.com
<b>IFP Ambetter HMO</b>	888-926-2164	provider_services@healthnet.com
<b>Health Net Employer Group HMO, POS, &amp; PPO</b>	800-641-7761	provider_services@healthnet.com
<b>Medicare (Individual &amp; Employer Group)</b>	800-929-9224	provider_services@healthnet.com
<b>Medi-Cal</b>	800-675-6110	N/A

## Health Net Commercial Formulary, Medi-Cal PDL and Medicare Part D Formulary Changes

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) <sup>1</sup>	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value <sup>1</sup> (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	

### Oral preparation

Zuruvae™ (zuranolone) capsule	NF	NF	Carved out to State				Treatment of postpartum depression in adults
-------------------------------	----	----	---------------------	--	--	--	--

### Injectable preparation

Adalimumab-adaz injection by Sandoz	Tier 4 <sup>2</sup>	NF	Carved out to State		Hadlima™ <sup>2</sup> , Humira® <sup>2</sup>		Now preferred for commercial line of business; biosimilar to Humira.
Amjevita™ (adalimumab-atto) injection	NF	NF	Carved out to State		Hadlima <sup>2</sup> , Humira <sup>2</sup> , adalimumab-adaz) injection by Sandoz <sup>2</sup>		Nonpreferred for commercial line of business; biosimilar to Humira.
Elevidys™ (delandistrogene moxparvovec-rokl) suspension for intravenous infusion	Medical Benefit <sup>2</sup>	Medical Benefit <sup>2</sup>	Medical Benefit <sup>2</sup>				Treatment of ambulatory pediatric patients aged four through five years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene.

**Health Net Commercial Formulary, Medi-Cal PDL and Medicare Part D Formulary Changes, *continued***

Medication	Status			Health Net Formulary Alternative(s)			Comments
	Commercial Tier 3 plan (Tier 4 plan)	Medicare Part D (6-Tier preferred) <sup>1</sup>	Medi-Cal	Commercial (Tier 1 or 2)	Medicare Part D Value <sup>1</sup> (Tier 1, 2, 3, 4, 5 or 6)	Medi-Cal	

**Injectable preparation**

Hadlima (adalimumab-bwwd) injection	Tier 4 <sup>2</sup>	NF	Carved out to State		Humira <sup>2</sup> , adalimumab-adaz) injection by Sandoz <sup>2</sup>		Now preferred for commercial line of business; biosimilar to Humira.
Roctavian™ (valoctocogene - roxaparvovec-rvox) suspension for intravenous infusion	Medical Benefit <sup>2</sup>	Medical Benefit <sup>2</sup>	Medical Benefit <sup>2</sup>				Treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without pre-existing antibodies to adeno-associated virus serotype 5 detected by an FDA-approved test.

**Topical preparation**

Vyjuvek™ (beremagene geperpavec-svdt) suspension for topical application	NF	NF	Carved out to State				Treatment of wounds in patients six months of age and older with dystrophic epidermolysis bullosa (DEB) with mutations(s) in the collagen type VII alpha 1 chain (COL7A1) gene.
--	----	----	---------------------	--	--	--	---

Note: The information above is subject to change. Please refer to Health Net’s provider portal online at [provider.healthnetcalifornia.com](http://provider.healthnetcalifornia.com) for the most up-to-date formulary status.

<sup>1</sup> Medicare Part D: Health Net Gold Select (HMO), Health Net Healthy Heart (HMO), Health Net Jade (HMO C-SNP), Health Net Ruby (HMO), Health Net Ruby Select (HMO), Health Net Sapphire (HMO), Health Net Violet 1 (PPO), Health Net Violet 2 (PPO), Health Net Violet 3 (PPO), Health Net Violet 4 (PPO)

<sup>2</sup> Prior authorization (PA) is required to verify that the member is eligible and satisfies clinical protocols to ensure appropriate use of the medication.

NF indicates nonformulary. These medications require member-specific medical reasons why formulary medications cannot be considered. Requests are reviewed via Health Net's prior authorization process.